Cardiology - Original Articles
June 7, 2018
Vol. 88 No. 2 (2018)
Net clinical benefit of anticoagulation therapy in the elderly patients with atrial fibrillation
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
3727
Views
599
Downloads
Authors
Old age remains one of the strongest risk factors for stroke in patients with atrial fibrillation (AF). Oral anticoagulation (OAC) is the most effective way to prevent thromboembolic disease in patients with atrial fibrillation (AF). Until few years ago, aspirin and vitamin-K antagonists (VKAs) were the primary agents used to prevent thromboembolic disease in patients with AF. The approval of non–vitamin K oral anticoagulants (NOACs) has now expanded the range of therapeutic agents available to providers. The authors highlight practical considerations regarding the selection and use of OAC in older adults to aid clinical decision making.
Altmetrics
Downloads
Download data is not yet available.
Citations
How to Cite
“Net Clinical Benefit of Anticoagulation Therapy in the Elderly Patients With Atrial Fibrillation”. 2018. Monaldi Archives for Chest Disease 88 (2). https://doi.org/10.4081/monaldi.2018.961.